, Papers of special note have been highlighted as either of interest (?) or of considerable interest (??) to readers

S. Kumar, S. Rajkumar, and A. Dispenzieri, Improved survival in multiple myeloma and the impact of novel therapies, Blood, vol.111, issue.5, pp.2516-2520, 2008.
DOI : 10.1182/blood-2007-10-116129

P. Moreau and C. Touzeau, Multiple Myeloma: From Front-Line to Relapsed Therapies, American Society of Clinical Oncology Educational Book, vol.35, pp.504-511, 2015.
DOI : 10.14694/EdBook_AM.2015.35.e504

S. Kumar, J. Lee, and J. Lahuerta, Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study, Leukemia, vol.16, issue.1, pp.149-157, 2012.
DOI : 10.1182/blood-2006-08-040410

Y. Tai, M. Dillon, and W. Song, Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu, Blood, vol.112, issue.4, pp.1329-1337, 2008.
DOI : 10.1182/blood-2007-08-107292

F. Van-rhee, S. Szmania, and M. Dillon, Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma, Molecular Cancer Therapeutics, vol.8, issue.9, pp.2616-2624, 2009.
DOI : 10.1158/1535-7163.MCT-09-0483

A. Jakubowiak, M. Offidani, and B. Pégourie, Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM, Blood, vol.127, issue.23, pp.2833-2840, 2016.
DOI : 10.1182/blood-2016-01-694604

P. Richardson, S. Jagannath, and P. Moreau, Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b???2 dose-escalation study, The Lancet Haematology, vol.2, issue.12, pp.516-527, 2015.
DOI : 10.1016/S2352-3026(15)00197-0

S. Lonial, M. Dimopoulos, and A. Palumbo, Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma, New England Journal of Medicine, vol.373, issue.7, pp.621-631, 2015.
DOI : 10.1056/NEJMoa1505654

F. Malavasi, S. Deaglio, and A. Funaro, Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology, Physiological Reviews, vol.88, issue.3, pp.841-886, 2008.
DOI : 10.1002/eji.1830240532

, ? This paper reviews the different functions of CD38

N. Van-de-donk, M. Janmaat, and T. Mutis, Monoclonal antibodies targeting CD38 in hematological malignancies and beyond, Immunological Reviews, vol.124, issue.1, pp.95-112, 2016.
DOI : 10.1034/j.1399-0039.2003.00037.x

P. Lin, R. Owens, and G. Tricot, Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma, American Journal of Clinical Pathology, vol.121, issue.4, pp.482-488, 2004.
DOI : 10.1309/74R4TB90BUWH27JX

M. De-weers, Y. Tai, and M. Van-der-veer, Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors, The Journal of Immunology, vol.186, issue.3, pp.1840-1848, 1950.
DOI : 10.4049/jimmunol.1003032

, ? This paper describes the preclinic activity of daratumumab on myeloma cells

M. Overdijk, S. Verploegen, and M. Bögels, Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma, mAbs, vol.120, issue.2, pp.311-321, 2015.
DOI : 10.1126/science.7973652

M. Overdijk, J. Jansen, and M. Nederend, The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fc?? Receptor???Mediated Cross-Linking, The Journal of Immunology, vol.114, issue.17, pp.807-813, 1950.
DOI : 10.1182/blood-2009-05-220285

J. Krejcik, T. Casneuf, and I. Nijhof, Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma, Blood, vol.128, issue.3, pp.384-394, 2016.
DOI : 10.1182/blood-2015-12-687749

X. Feng, L. Zhang, and C. Acharya, Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma, Clinical Cancer Research, vol.23, issue.15, 2017.
DOI : 10.1158/1078-0432.CCR-16-3192

I. Nijhof, R. Groen, and W. Noort, Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib, Clinical Cancer Research, vol.21, issue.12, pp.2802-2810, 2015.
DOI : 10.1158/1078-0432.CCR-14-1813

H. Lokhorst, T. Plesner, and J. Laubach, Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma, New England Journal of Medicine, vol.373, issue.13, pp.1207-1219, 2015.
DOI : 10.1056/NEJMoa1506348

, ? This paper presents the results of the phase 1 dose-escalation cohort evaluating daratumumab single agent in relapsed myeloma patients

S. Lonial, B. Weiss, and S. Usmani, Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial, The Lancet, vol.387, issue.10027, pp.1551-1560, 2016.
DOI : 10.1016/S0140-6736(15)01120-4

, ?? This paper presents the results of the phase 1?2 evaluating daratumumab single agent in advanced relapsed myeloma patients

T. Plesner, H. Arkenau, and P. Gimsing, Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma, Blood, vol.128, issue.14, 2016.
DOI : 10.1182/blood-2016-07-726729

S. Usmani, B. Weiss, and T. Plesner, Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma, Blood, vol.128, issue.1, 2016.
DOI : 10.1182/blood-2016-03-705210

I. Nijhof, T. Casneuf, and J. Van-velzen, CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma, Blood, vol.128, issue.7, pp.959-970, 2016.
DOI : 10.1182/blood-2016-03-703439

E. Boyle, M. Petillon, and C. Herbaux, Daratumumab in combination with dexamethasone in resistant or refractory multiple myeloma: primary results of the IFM2014-04 Trial, Blood, vol.128, issue.22, pp.2138-2138, 2016.

M. Dimopoulos, A. Oriol, and H. Nahi, Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma, New England Journal of Medicine, vol.375, issue.14, pp.1319-1331, 2016.
DOI : 10.1056/NEJMoa1607751

, ?? This paper presents the results of the phase 3 trial demonstrating the superiority of the triplet daratumumab?lenalidomide? dexamethasone over lenalidomide -dexamethasone in relapsed myeloma patients

P. Moreau, J. Kaufman, and H. Sutherland, Efficacy of daratumumab , lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone for relapsed or refractory multiple myeloma among patients with 1 to 3 prior lines of therapy based on previous treatment exposure: updated analysis of pollux, Blood, vol.128, issue.22, pp.489-489, 2016.

A. Palumbo, A. Chanan-khan, and K. Weisel, Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma, New England Journal of Medicine, vol.375, issue.8, pp.754-766, 2016.
DOI : 10.1056/NEJMoa1606038

, ?? This paper presents the results of the phase 3 trial demonstrating the superiority of the triplet daratumumab?bortezomib? dexamethasone over bortezomib?dexamethasone in relapsed myeloma patients

M. Mateos, E. J. Barreto, and W. , Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of castor, Blood, vol.128, issue.22, pp.1150-1150, 2016.

H. Avet-loiseau, T. Casneuf, and C. Chiu, Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone, Blood, vol.128, issue.22, pp.246-246, 2016.

N. Munshi, H. Avet-loiseau, and A. Rawstron, Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma, JAMA Oncology, vol.3, issue.1, pp.28-35, 2017.
DOI : 10.1001/jamaoncol.2016.3160

M. Oostendorp, L. Van-bueren, J. Doshi, and P. , When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy, Transfusion, vol.39, issue.6pt2, pp.1555-1562, 2015.
DOI : 10.1046/j.1537-2995.1999.39070763.x

C. Chapuy, R. Nicholson, and M. Aguad, Resolving the daratumumab interference with blood compatibility testing, Transfusion, vol.268, issue.Suppl 15, pp.1545-1554, 2015.
DOI : 10.1126/scisignal.2002700

C. Chapuy, M. Aguad, and R. Nicholson, International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing, Transfusion, vol.55, issue.12, pp.2964-2972, 2016.
DOI : 10.1111/trf.13267

P. Moreau, N. Van-de-donk, S. Miguel, and J. , Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma, Drugs, vol.100, issue.1, pp.853-867, 2016.
DOI : 10.3324/haematol.2014.107714

N. Van-de-donk, H. Otten, E. Haddad, and O. , Abstract, Clinical Chemistry and Laboratory Medicine (CCLM), vol.5, issue.6, pp.1105-1109, 2016.
DOI : 20152126602

S. Kumar, B. Paiva, and K. Anderson, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, The Lancet Oncology, vol.17, issue.8, pp.328-346, 2016.
DOI : 10.1016/S1470-2045(16)30206-6

A. Nooka, N. Joseph, and L. Boise, Clinical efficacy of daratumumab , pomalidomide and dexamethasone in relapsed, refractory myeloma patients: utility of retreatment with daratumumab among refractory patients, Blood, vol.128, issue.22, pp.492-492, 2016.

S. Usmani, H. Nahi, and M. Mateos, Open-label, multicenter, dose escalation Phase 1b study to assess the subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple Myeloma (PAVO), Blood, vol.128, issue.22, pp.1149-1149, 2016.

F. De-larrea, C. Kyle, R. Durie, and B. , Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group, Leukemia, vol.3, issue.4, pp.780-791, 2013.
DOI : 10.1056/NEJMoa1114083

T. Martin, G. Mannis, and A. Chari, Phase Ib study of isatuximab and carfilzomib in relapse and refractory multiple Myeloma, Blood, vol.128, issue.22, pp.2111-2111, 2016.

L. Moreno, A. Zabaleta, and D. Alignani, Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 monoclonal antibody isatuximab in Multiple Myeloma (MM), Blood, vol.128, issue.22, pp.2105-2105, 2016.

P. Richardson, J. Mikhael, and S. Usmani, Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM), Clinical Lymphoma Myeloma and Leukemia, vol.17, issue.1, pp.2123-2123, 2016.
DOI : 10.1016/j.clml.2017.03.028

M. Raab, M. Chatterjee, and H. Goldschmidt, A Phase I/IIa study of the CD38 antibody MOR202 alone and in combination with pomalidomide or lenalidomide in patients with relapsed or refractory multiple myeloma, Blood, vol.128, issue.22, pp.1152-1152, 2016.